课题基金 / 基金详情

Generation of a Modified DT_IL3 Fusion Toxin

Generation of a Modified DT_IL3 Fusion Toxin
改良 DT_IL3 融合毒素的生成
批准号：
7483540
负责人：
JOHANNA Catharina VANDERSPEK
金额：
$12.28万
依托单位：
ANJIN GROUP, INC.
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
项目状态：
已结题
起止时间：
2008-09-01 至 2009-08-28
来源：
https://reporter.nih.gov/project-details/7483540
关键词：
Adverse effectsBiological AssayBlood VesselsCellsChimeric ProteinsClassClinicalClinical TreatmentClinical TrialsCutaneousDenileukin DiftitoxDevelopmentDiphtheria ToxinExtravasationFusion ToxinGenerationsGoalsHumanIn VitroInterleukin 2 ReceptorInterleukin-3Interleukin-3 ReceptorLigandsPatientsPharmaceutical PreparationsPhaseProteinsPublic HealthRangeRecurrenceSalesT-Cell LymphomaTargeted ToxinsTestingTherapeuticTherapeutic AgentsToxinUnited States Food and Drug Administrationbasecytokinecytotoxicityhuman IL3RA proteinleukemiamutantnumb proteinreceptor

项目摘要

项目成果

JOHANNA Catharina VANDERSPEK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A number of protein fusion toxins, composed of the diphtheria toxin (DT) toxophore and a targeting ligand, have been assembled and tested in Phase I clinical trials for the treatment of leukemias. To date, the only FDA approved protein fusion toxin is ONTAK. ONTAK is a DT, interleukin-2 receptor-targeted fusion toxin used to treat persistent or recurrent, cutaneous T-cell lymphoma. Sales of this drug range between $30 and $40M annually. DT-based protein fusion toxins targeting the interleukin-3 (IL-3) receptor have produced encouraging early clinical results. The goals of this Phase I proposal are to create a DT-IL3 fusion toxin, using a DT toxophore that has been modified to reduce potential for induction of vascular leak, that is as potent as the existing DT-IL3 fusion toxin. Vascular leakage in humans is a common side effect of fusion toxin therapy and can inhibit development of this class of therapeutic agent. A reduced side effect profilethe chances of a DT-IL3 toxin becoming available to treat patients with AML. reat AML. PUBLIC HEALTH RELEVANCE: This project seeks to determine if a DT-IL3 fusion toxin with reduce VLS profile can developed. This fusion toxin could provide a wider therapeutic window and thereby enhance
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Further Analysis of a VLS Modified IL-2 Receptor Targeted Toxin
  • 批准号：
    7480070
  • 项目类别：
  • 资助金额：
    $14.75万
  • 财政年份：
    2008
  • 负责人：
    JOHANNA Catharina VANDERSPEK
  • 依托单位：
    ANJIN GROUP, INC.
Modified Diphtheria Toxin IL-7 Fusion Toxins
  • 批准号：
    7110847
  • 项目类别：
  • 资助金额：
    $15.21万
  • 财政年份：
    2006
  • 负责人：
    JOHANNA Catharina VANDERSPEK
  • 依托单位：
    ANJIN GROUP, INC.
An IL-2 Receptor Targeted Toxin with Reduced VLS
  • 批准号：
    6883320
  • 项目类别：
  • 资助金额：
    $14.48万
  • 财政年份：
    2005
  • 负责人：
    JOHANNA Catharina VANDERSPEK
  • 依托单位：
    ANJIN GROUP, INC.
海外基金